Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: Renal cell carcinoma cells cultured in suspension Raw sequence reads

PROVIDER: PRJNA1083331 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR28210702_1.fastq.gz	Fastqsanger.gz
	SRR28210702_2.fastq.gz	Fastqsanger.gz
	SRR28210703_1.fastq.gz	Fastqsanger.gz
	SRR28210703_2.fastq.gz	Fastqsanger.gz
	SRR28210704_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Homo sapiens

Project description:Renal cell carcinoma cell cultured in suspension Raw sequence reads

| PRJNA1083286 | ENA

Homo sapiens

Project description:Homo sapiens renal cell carcinoma Raw sequence reads

| PRJNA813358 | ENA

Morus alba Raw protein sequence reads

Project description:Morus alba L. Raw protein sequence reads and sequence

2024-02-08 | PXD049451 |

Homo sapiens

Project description:Renal Cell Carcinoma

| PRJNA94925 | ENA

dePillis2013 - Mathematical modeling of regulatory T cell effects on renal cell carcinoma treatment

Project description:Mathematical modeling of regulatory T cell effects on renal cell carcinoma treatment Lisette dePillis 1, , Trevor Caldwell 2, , Elizabeth Sarapata 2, and Heather Williams 2, 1. Department of Mathematics, Harvey Mudd College, Claremont, CA 91711 2. Harvey Mudd College, Claremont, CA 91711, United States, United States, United States Abstract We present a mathematical model to study the effects of the regulatory T cells (Treg) on Renal Cell Carcinoma (RCC) treatment with sunitinib. The drug sunitinib inhibits the natural self-regulation of the immune system, allowing the effector components of the immune system to function for longer periods of time. This mathematical model builds upon our non-linear ODE model by de Pillis et al. (2009) [13] to incorporate sunitinib treatment, regulatory T cell dynamics, and RCC-specific parameters. The model also elucidates the roles of certain RCC-specific parameters in determining key differences between in silico patients whose immune profiles allowed them to respond well to sunitinib treatment, and those whose profiles did not. Simulations from our model are able to produce results that reflect clinical outcomes to sunitinib treatment such as: (1) sunitinib treatments following standard protocols led to improved tumor control (over no treatment) in about 40% of patients; (2) sunitinib treatments at double the standard dose led to a greater response rate in about 15% the patient population; (3) simulations of patient response indicated improved responses to sunitinib treatment when the patient's immune strength scaling and the immune system strength coefficients parameters were low, allowing for a slightly stronger natural immune response. Keywords: Renal cell carcinoma, mathematical modeling., sunitinib, immune system, regulatory T cells.

2024-09-02 | BIOMD0000000908 | BioModels

Homo sapiens

Project description:SUDHL-4 cells: suspension vs. co-cultured with HK cells

| PRJNA213415 | ENA

Homo sapiens

Project description:Global transcriptional analysis of renal cell carcinoma cells.

| PRJDB8377 | ENA

Arabidopsis thaliana

Project description:Growth of suspension-cultured cells

| PRJNA97073 | ENA

Homo sapiens

Project description:cultured human HCC cells - erdafitinib - Transcriptome - Raw sequence reads